The Neuroimaging Core will continue to provide the necessary support for all neuroimaging studies performed by ADRC investigators. The Core has had a tri-fold purpose within the ADRC, which it will continue to pursue: 1) methodological development and validation of advanced structural and functional imaging techniques targeting the unique challenges inherent in in vivo studies of the aging brain, 2) development and maintenance of an in vivo """"""""brain bank"""""""" of high-resolution structural magnetic resonance imaging (MRI) data, and 3) providing support for the multidisciplinary training of future imaging researchers who will address questions specific to neurodegenerative disease. We have made substantial progress over the last funding period in novel MRI applications including innovative morphometric techniques in collaboration with the UCLA Laboratory of Neuroimaging and the Carnegie Mellon University Robotics Institute, and the development of non-invasive arterial spin-labeling MRI perfusion imaging. As a result of advances in positron emission tomography (PET) techniques highly relevant and supportive of the mission of the ADRC, the proposed Core application will expand the role of PET imaging to encompass in vivo quantification of amyloid load in normal aging, mild cognitive impairment, and AD. The complementary use of a range of neuroimaging tools is fostered by collaborations among investigators utilizing Core resources. The Neuroimaging Core is also highly committed to the mentoring of junior faculty, and pre- and post-doctoral trainees in the validation and translation of advanced brain imaging techniques to aging and AD research.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005133-24
Application #
7406706
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
24
Fiscal Year
2007
Total Cost
$216,468
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Kamboh, M Ilyas (2018) A Brief Synopsis on the Genetics of Alzheimer's Disease. Curr Genet Med Rep 6:133-135
Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10
La Joie, Renaud; Ayakta, Nagehan; Seeley, William W et al. (2018) Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement :
Rodakowski, Juleen; Reynolds 3rd, Charles F; Lopez, Oscar L et al. (2018) Developing a Non-Pharmacological Intervention for Individuals With Mild Cognitive Impairment. J Appl Gerontol 37:665-676
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Hadjichrysanthou, Christoforos; McRae-McKee, Kevin; Evans, Stephanie et al. (2018) Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. J Alzheimers Dis 66:587-600
Ritzel, Rodney M; Lai, Yun-Ju; Crapser, Joshua D et al. (2018) Aging alters the immunological response to ischemic stroke. Acta Neuropathol 136:89-110
Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71
Cohen, Ann D; McDade, Eric; Christian, Brad et al. (2018) Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. Alzheimers Dement 14:743-750

Showing the most recent 10 out of 667 publications